Sweden’s Affibody Inks Inmagene China R&D Pact
Affibody And Inmagene Will Focus On Auto-Immune Diseases
Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.
You may also be interested in...
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.